Proton Pump Inhibitor Lansoprazole 30mg Lyophilized Powder For Injection Anti Acid

Proton Pump Inhibitor Lansoprazole 30mg Lyophilized Powder For Injection Anti Acid

Product : Lansoprazole for Injection

Specification : Lyophilized, 30mg

Standard : BP, USP

Packing : 50vials/box

Description :

Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by TAP Pharmaceutical Products. Lansoprazole has been marketed for many years and is one of several PPI’s available.

Indications and Dosages :

➤➤To treat duodenal ulcers and maintain healed duodenal ulcers

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Adults. 15 to 30 mg daily before morning meal for 4 wk. Maximum: 30 mg daily.

➤➤To treat gastric ulcers

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Adults. 15 to 30 mg daily before morning meal for up to 8 wk.

➤➤To treat gastroesophageal reflux disease

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Adults. 15 mg daily before morning meal for up to 8 wk.

➤➤To treat nonerosive gastroesophageal reflux disease

capsules (dexlansoprazole)

Adults. 30 mg once daily for 4 wk.

➤➤To heal all grades of erosive esophagitis

capsules (dexlansoprazole)

Adults. 60 mg once daily for up to 8 wk.

➤➤To maintain healed erosive esophagitis

capsules (dexlansoprazole)

Adults. 30 mg once daily.

➤➤To treat erosive esophagitis

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Adults. Initial: 30 mg daily before morning meal for up to 8 wk. Continued another 8 wk if indicated. Maintenance: 15 mg daily.

➤➤To treat erosive esophagitis short-term (up to 7 days) in patients unable to take oral medication

i.v. infusion

Adults. 30 mg daily infused over 30 min for up to 7 days.

➤➤To treat pathological hypersecretory conditions, such as Zollinger-Ellison syndrome

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Adults. Initial: 60 mg daily before morning meal, increased as needed according to patient’s condition. Doses exceeding 120 mg/day administered in divided doses. Maximum: 180 mg daily.

➤➤To eradicate Helicobacter pylori and reduce risk of duodenal ulcer recurrence

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Adults. 30 mg plus 1 g amoxicillin and 500 mg clarithromycin every 12 hr before meals for 10 to 14 days. Or, 30 mg plus 1 g amoxicillin t.i.d. before meals for 14 days.

➤➤To treat symptomatic pediatric gastroesophageal reflux disease

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Children ages 12 to 17. 15 mg daily for up to 8 wk.

Children ages 1 to 11 weighing 30 kg (66 lb) or less. 15 mg daily for up to 12 wk.

Children ages 1 to 11 weighing more than 30 kg. 30 mg daily for up to 12 wk.

➤➤To treat symptomatic pediatric erosive esophagitis

delayed-release capsules, delayed-release suspension, delayed-release orally disintegrating tablets

Children ages 12 to 17. 30 mg daily for up to 8 wk.

Children ages 1 to 11 weighing 30 kg (66 lb) or less. 15 mg daily for up to 12 wk.

Children ages 1 to 11 weighing more than 30 kg. 30 mg daily for up to 12 wk.

➤➤To treat frequent heartburn

e.r. capsules (prevacid 24-hr)

Adults. 1 capsule daily for 14 days. May repeat course every 4 months.

Route      Onset      Peak      Duration

P.O.        1–3 hr    Unknown  Over 24 hr

Pharmacodynamics

Lansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours.

Mechanism of action

Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.